Thailand To Allow Generic Of Taxotere Under CL Policy
This article was originally published in PharmAsia News
Executive Summary
Thailand's drug authority says it intends to use its compulsory licensing policy to import a generic of the Sanofi Aventis breast cancer drug Taxotere (docetaxel). The Government Pharmaceutical Organisation says it also will follow through on plans to use its CL policy to import two other cancer generics, for Roche/OSI Pharmaceuticals' Tarceva (erlotinib hydrochloride) and the Novartis drug Femara (letrozole). The Taxotere generic is to be supplied by India's Dabur Pharma, which is expected to deliver its first thousand doses soon, at 1 percent of the Sanofi price. (Click here for more